New combo therapy targets tough prostate cancer

NCT ID NCT07319871

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 17 times

Summary

This early-stage study tests a new drug combination for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The treatment uses a T-cell redirecting agent (pasritamig) plus an A2a receptor blocker to help the immune system attack cancer cells. About 40 participants will be enrolled to find the safest dose and check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Columbia University Medical Center
RECRUITING

New York, New York, 10032, United States
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
Royal Marsden Hospital
RECRUITING

Sutton, SM2 5PT, United Kingdom
The Christie NHS Foundation Trust Christie Hospital
RECRUITING

Manchester, M20 4BX, United Kingdom
University Hospitals Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States

Conditions

Explore the condition pages connected to this study.

PROSTATIC NEOPLASMS